Vericel (NASDAQ:VCEL – Get Free Report) and Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.
Valuation & Earnings
This table compares Vericel and Pasithea Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $276.26 million | 5.80 | $16.52 million | $0.31 | 101.42 |
| Pasithea Therapeutics | N/A | N/A | -$13.90 million | ($5.09) | -0.15 |
Profitability
This table compares Vericel and Pasithea Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 5.98% | 5.17% | 3.67% |
| Pasithea Therapeutics | N/A | -97.88% | -87.96% |
Institutional & Insider Ownership
23.9% of Pasithea Therapeutics shares are held by institutional investors. 5.2% of Vericel shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Vericel has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Vericel and Pasithea Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 0 | 3 | 5 | 0 | 2.63 |
| Pasithea Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
Vericel currently has a consensus price target of $56.00, suggesting a potential upside of 78.12%. Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 283.98%. Given Pasithea Therapeutics’ higher probable upside, analysts plainly believe Pasithea Therapeutics is more favorable than Vericel.
Summary
Vericel beats Pasithea Therapeutics on 11 of the 13 factors compared between the two stocks.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
